As of Apr 24
| -0.375 / -5.85%|
The 3 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +49.25% increase from the last price of 6.03.
The current consensus among 4 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.